Laurus Labs Q4 FY26 Revenue Up 23% to INR6,813 Crores

Laurus Labs reported 23% revenue growth to INR6,813 crores in FY26 with EBITDA margins expanding to 26.8%.
CDMO business grew 38% to INR1,896 crores while Generics division delivered 18% growth to INR4,733 crores.
Company announced INR3,000 crores capex plan over next 2 years for capacity expansion across multiple facilities.
Management maintained confidence in sustaining 29% EBITDA margins in FY27 with strong CDMO pipeline visibility.